Top Analyst Reports for Novo Nordisk, Walmart & AMD
https://www.zacks.com/commentary/2202579/top-analyst-reports-for-novo-nordisk-walmart-amd?cid=CS-ZC-FT-research_daily-2202579
Dec 27, 2023 - Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Walmart Inc. (WMT) and Advanced Micro Devices, Inc. (AMD).
0
Why You Should Invest in Encompass Health (EHC) Stock for Now
https://www.zacks.com/stock/news/2202750/why-you-should-invest-in-encompass-health-ehc-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2202750
Dec 27, 2023 - Encompass Health (EHC) is well-poised for growth on the back of growing revenues, an aging U.S. population, joint ventures and solid cash reserves.
0
Sarepta (SRPT) Seeks Label Expansion for DMD Gene Therapy
https://www.zacks.com/stock/news/2202279/sarepta-srpt-seeks-label-expansion-for-dmd-gene-therapy?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2202279
Dec 26, 2023 - Sarepta (SRPT) files a supplement with the FDA seeking to expand its recently-approved gene therapy Elevidys' label to treat all DMD patients, regardless of age and ambulatory status.
0
Jazz Pharmaceuticals' (JAZZ) PTSD Drug Misses Study Goals
https://www.zacks.com/stock/news/2201716/jazz-pharmaceuticals-jazz-ptsd-drug-misses-study-goals?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2201716
Dec 22, 2023 - After a mid-stage study fails to show any improvement in its primary or secondary endpoints, Jazz (JAZZ) plans to scrap the development of its PTSD drug.
0
Merck's (MRK) Chronic Cough Drug Gets Another CRL From FDA
https://www.zacks.com/stock/news/2201156/merck-s-mrk-chronic-cough-drug-gets-another-crl-from-fda?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2201156
Dec 21, 2023 - Per the FDA, the data submitted by Merck (MRK) for its chronic cough drug did not provide sufficient evidence to prove its clinical benefit in patients.
0
Weighing Their Chances: 5 Leading Healthcare Companies Fight for Market Share in the $100 Billion Weight-Loss Industry
https://www.fool.com/investing/2023/12/21/weighing-their-chances-5-leading-healthcare-compan/?source=iedfolrf0000001
Dec 21, 2023 - Which weight-loss stocks are good buys today?
0
Looking to Invest in the Next Big Craze Like Ozempic? This 1 Emerging Field Could Be It.
https://www.fool.com/investing/2023/12/21/looking-to-invest-in-next-big-craze-like-ozempic/?source=iedfolrf0000001
Dec 21, 2023 - Diabetes and weight-loss drugs won't be the hottest category of medicines forever.
0
Why Novo Nordisk Stock Was Up on a Down Day for the Market
https://www.fool.com/investing/2023/12/20/why-novo-nordisk-stock-was-up-on-a-down-day-for-th/?source=iedfolrf0000001
Dec 20, 2023 - As if the company's top two products weren't popular enough, a new media report made them even more appealing.
0
FDA Accepts Merck's (MRK) BLA for 21-Valent Pneumococcal Jab
https://www.zacks.com/stock/news/2200645/fda-accepts-merck-s-mrk-bla-for-21-valent-pneumococcal-jab?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200645
Dec 20, 2023 - The FDA grants priority review to Merck's (MRK) filing seeking approval for its 21-valent pneumococcal conjugate vaccine in adults. A final decision is expected in June 2024.
0
4 Drug Stocks Rising More Than 40% in 2023 With Room to Grow
https://www.zacks.com/stock/news/2200461/4-drug-stocks-rising-more-than-40-in-2023-with-room-to-grow?cid=CS-ZC-FT-analyst_blog|investment_ideas-2200461
Dec 20, 2023 - Novo Nordisk (NVO), Journey Medical Corporation (DERM), Lyra Therapeutics (LYRA) and Fusion Pharmaceuticals (FUSN) have returned 40% or higher year to date and have room for more growth in 2024.
0